Přehled o publikaci
2024
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
KÝR, Michal, Peter MÚDRY, Kristýna POLÁŠKOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Regina DEMLOVÁ et. al.Basic information
Original name
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
Authors
KÝR, Michal, Peter MÚDRY, Kristýna POLÁŠKOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Regina DEMLOVÁ, Jana KUBÁTOVÁ, Eva HLAVÁČKOVÁ, Kateřina ČERNÁ PILÁTOVÁ, Pavel MAZANEK, Klára VEJMĚLKOVÁ, Vítězslav DUŠEK, Pavel TINKA, Martin BALÁŽ, Tomáš MERTA, Zuzana KUTTNEROVÁ, Terézia TUREKOVÁ, Zdeněk PAVELKA, Petra POKORNÁ, Hana PÁLOVÁ, Marie MLNAŘÍKOVÁ, Marta JEŽOVÁ, Renata KELLNEROVÁ, Šárka KOZÁKOVÁ, Ondřej SLABÝ, Dalibor VALÍK and Jaroslav ŠTĚRBA
Edition
International journal of cancer, HOBOKEN, International Union Against Cancer, 2024, 0020-7136
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
References:
Organization
Lékařská fakulta – Repository – Repository
UT WoS
001260796700001
EID Scopus
2-s2.0-85197461804
Keywords in English
cancer vaccine; immunotherapy; metronomic chemotherapy; N-of-1; rare cancer
Links
LX22NPO5102, research and development project. MUNI/A/1395/2022, interní kód Repo. MUNI/A/1625/2023, interní kód Repo. NV19-03-00562, research and development project. 101059788, interní kód Repo. CZECRIN IV, large research infrastructures.
Changed: 13/3/2025 00:50, RNDr. Daniel Jakubík
Abstract
V originále
A lot of hope for high-risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single-agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high-risk solid tumors using the N-of-1 approach in real-world scenario. A total of 160 evaluable events occurred in 48 patients during the 4-year follow-up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check-point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents.
